Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
301-315 of 355
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
CME/CEEmpowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
Joyce O'Shaughnessy, MD
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
CME/CEBringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
David H. Ilson, MD, PhD
Sunnie Kim, MD
Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
Jyoti Patel, MD
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®Maximizing Adherence and Persistence via Patient Engagement
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
- advertisement
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®Recent updates from adjuvant trials in HR+/HER2- EBC
Nadia Harbeck, MD, PhD
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
- MinuteCE®
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®Treatment Intensification in HR+/HER2- EBC: Who and When?
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
MinuteCE®Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
Nadia Harbeck, MD, PhD
- advertisement
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Interprofessional Coordination of Adverse Event Management
MinuteCE®Interprofessional Coordination of Adverse Event Management
Nadia Harbeck, MD, PhD
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
CME/CEWarm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
Caroline Piatek, MD
Irina Murakhovskaya, MD
